kicked off on Monday, with Verve Therapeutics Inc (NASDAQ: VERV) stock price up 4.14% from the previous day of trading, before settling in for the closing price of $5.55. VERV’s price has ranged from $4.30 to $13.63 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 136.15% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged -13.49%. With a float of $66.18 million, this company’s outstanding shares have now reached $88.76 million.
In an organization with 274 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 84.37%, operating margin of -707.23%, and the pretax margin is -613.51%.
Verve Therapeutics Inc (VERV) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Verve Therapeutics Inc is 25.47%, while institutional ownership is 69.88%. The most recent insider transaction that took place on Dec 02 ’24, was worth 3,130. In this transaction Chief Financial Officer of this company sold 555 shares at a rate of $5.64, taking the stock ownership to the 5,380 shares. Before that another transaction happened on May 14 ’24, when Company’s insider bought 76,000 for $6.26, making the entire transaction worth $475,760. This insider now owns 342,509 shares in total.
Verve Therapeutics Inc (VERV) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.67 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -13.49% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 5.30% during the next five years compared to -42.43% drop over the previous five years of trading.
Verve Therapeutics Inc (NASDAQ: VERV) Trading Performance Indicators
Here are Verve Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 12.65. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 15.88.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.35, a number that is poised to hit -0.65 in the next quarter and is forecasted to reach -2.69 in one year’s time.
Technical Analysis of Verve Therapeutics Inc (VERV)
Let’s dig in a bit further. During the last 5-days, its volume was 0.96 million. That was inferior than the volume of 1.47 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 23.51%. Additionally, its Average True Range was 0.56.
During the past 100 days, Verve Therapeutics Inc’s (VERV) raw stochastic average was set at 27.54%, which indicates a significant decrease from 33.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 87.06% in the past 14 days, which was lower than the 97.53% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.89, while its 200-day Moving Average is $5.99. However, in the short run, Verve Therapeutics Inc’s stock first resistance to watch stands at $5.98. Second resistance stands at $6.18. The third major resistance level sits at $6.37. If the price goes on to break the first support level at $5.59, it is likely to go to the next support level at $5.40. Assuming the price breaks the second support level, the third support level stands at $5.20.
Verve Therapeutics Inc (NASDAQ: VERV) Key Stats
With a market capitalization of 513.24 million, the company has a total of 88,796K Shares Outstanding. Currently, annual sales are 32,330 K while annual income is -198,710 K. The company’s previous quarter sales were 13,080 K while its latest quarter income was -50,040 K.
